The DOI matches its Crossref record; 63 of the 65 references it cites were found in a registry or an index.
CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges
Abstract
Cancer immunotherapy, consisting of antibodies, adoptive T-cell transfer, vaccines and cytokines, is a novel strategy for fighting cancer by artificially stimulating the immune system. It has developed rapidly in recent years, and its efficacy in hematological malignancies and solid tumors has been remarkable. It is regarded as one of the most promising methods for cancer therapy. The current trend in immunotherapy research seeks to improve its efficacy and to ensure the safety of cancer immunotherapy through the use of gene editing technologies. As it is an efficient and simple technology, the CRISPR-Cas9 system is highly anticipated to dramatically strengthen cancer immunotherapy. Intensive research on the CRISPR-Cas9 system has provided increasing confidence to clinicians that this system can be put into clinical use in the near future. This paper reviews the application and challenges of CRISPR-Cas9 in this field, based on various strategies including adaptive cell therapy and antibody therapy, and also highlights the function of CRISPR/Cas9 in the screening of new cancer targets.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Xia, 2019, Applications and advances of CRISPR-Cas9 in cancer immunotherapy, J Med Genet, 56, 4, 10.1136/jmedgenet-2018-105422”
Cited work 10.1136/jmedgenet-2018-105422 · retracted 2026-04-14 · notice 10.1136/jmg-2026-56-1-2019ret · this paper published 2019-12-02
Citations
Cites
1 retracted
Retracted: Applications and advances of CRISPR-Cas9 in cancer immunotherapy
Xia, A., He, Q., Wang, J., Zhu, J., Sha, Y., Sun, B., & Lu, X. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2018-105422 · Cited by 61
RetractedDevelopment and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,331
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001
Self-citationKim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.
Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.015 · Cited by 1,571
Cited by
Using Gene Editing Approaches to Fine-Tune the Immune System
Pavlovic, K., Tristán‐Manzano, M., Maldonado‐Pérez, N., Cortijo-Gutierréz, M., Sánchez-Hernández, S., Justicia-Lirio, P., Carmona-Luque, M. D., Herrera, C., Martín, F., & Benabdellah, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.570672 · Cited by 52
Nanoparticles for Cancer Immunotherapy: Innovations and Challenges
Fallatah, M., Alradwan, I. A., Fayez, N. A., Aodah, A. H., Alkhrayef, M. N., Majrashi, M. A., & Jamous, Y. F. (2025) · Pharmaceuticals · doi:10.3390/ph18081086 · Cited by 56
“Addressing these hurdles is essential to fully realize its therapeutic potential and translate these innovations into safe and effective clinical applications [248].”
Hosseini, S. A., Jouneghani, A. S., Ghatrehsamani, M., Yaghoobi, H., Elahian, F., & Mirzaei, S. A. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.018 · Cited by 29
CRISPR/Cas9: an overview of recent developments and applications in cancer research
Devi, S. N., Rana, R., Malik, P., & Ganguly, N. K. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001081 · Cited by 14
“Preclinical studies show PD-1 knockout CAR-T cells improve persistence and tumor clearance in mouse models [60] .”
BackgroundZhi, L., Su, X., Yin, M., Zhang, Z., Lü, H., Niu, Z., Guo, C., Zhu, W., & Zhang, X. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104436 · Cited by 15
Metadata
- Authors
- Chen, M., Xu, J., Zhou, Y., Zhang, S., & Zhu, D.
- Affiliations
- Bengbu Medical College (CN)
- Department of Rehabilitation, Huai'an Second People's Hospital, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China, 223001
- Fudan University (CN)
- Renmin Hospital of Wuhan University (CN)
- Corresponding author
- Zhang, Silin
- Zhu, Di
- Venue
- Briefings in Functional Genomics
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-12-02
- Volume
- 19
- Issue
- 3
- Pages
- 183-190
- ISSN
- 2041-2647 (ISSN-L)
- 2041-2657
- OpenAlex
- W2992262155
- Cited by
- 12
- References
- 65
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2022: 1 · 2021: 1 · 2020: 2
- FWCI
- 0.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Briefings in Functional Genomics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Project on Joint Translational Research of the School of Pharmacy and Minhang Hospital (RO-MY201712)
- National Natural Science Foundation of China (81872895)
- Projects on Science and Technology Commission of Shanghai (18ZR1403900)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, genome editing, cancer immunotherapy, adoptive T cell therapy, antibody therapy, cancer vaccines, cytokines, hematologic malignancies, solid tumors, gene editing safety
- MeSH terms
- Gene Editing, Humans, Immunotherapy, Neoplasms, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges. https://app.cochat.ai/papers/10.1093/bfgp/elz027
- The paper
- Chen, M., Xu, J., Zhou, Y., Zhang, S., & Zhu, D. (2020). CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges. Briefings in Functional Genomics. https://doi.org/10.1093/bfgp/elz027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.